

United States Patent and Trademark Office
- Sales Receipt -

04/20/2006 DWILLIA1 00000002 081290 09788110

01 FC:2201 100.00 DA

APR 13 2006

PATENT
Attorney Docket No. UCSD-07017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Maurizio Zanetti
 Serial No.: 09/788,110 Group No.: 1642
 Filed: 02/15/2001 Examiner: Ungar, S.
 Entitled: Composition and Method For Inducing and Enhancing A Telomerase
 Reverse Transcriptase-Reactive Cytotoxic T Lymphocyte Response


**AMENDMENT AND RESPONSE TO
FINAL OFFICE ACTION MAILED FEBRUARY 13, 2006**

Central Fax No. 571/273-8300 &
 571/273-0837
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is being facsimile transmitted to the USPTO or is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 13, 2006

By: 
 Christine A. Lekutis

Dear Madam:

The following communication is responsive to the Final Office Action mailed February 13, 2006, having a deadline for provoking an Advisory Action of April 13, 2006. Applicant respectfully requests reconsideration of the application in view of the following:
 amendments to the specification beginning on page 2;
 amendments to the claims reflected in the listing of claims beginning on page 3; and
 remarks and arguments beginning on page 6.


PATENT
Attorney Docket No. UCSD-07017

Examiner contends that support is lacking for HLA-A2.1-restricted, human TRT peptides from seven to fifteen residues in length (Final Office Action, Section 7, pp. 4 and 5). Although Applicant respectfully disagrees that the claims lack enablement for HLA-A2.1-restricted hTRT peptides that are shorter or longer than nine amino acids, as discussed above in Sections 2 and 3, Applicant has amended Claims 19 and 26 to recite a "human telomerase reverse transcriptase (TRT) peptide nine amino acid residues in length." Support for this amendment is found in various locations in the application as originally filed including the Examples 10 and 11, and Tables II, IV and VI, which teach exemplary HLA-A2.1-restricted hTRT nonamers. Therefore, Applicant contends that the amended claims are enabled and respectfully requests that this rejection be withdrawn.

CONCLUSION

Applicant believes the amendments and arguments set forth above traverse the Examiner's rejections and therefore request that these grounds for rejection be withdrawn. However, should the Examiner believe a telephone interview would aid in the prosecution of this application, the Applicant encourages the Examiner to call the undersigned collect.


Dated: April 13, 2006



Christine A. Lekutis
Registration No. 51,934

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105

415.904.6500
415/904-6510 fax



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)		Docket Number (Optional)
FY 2005 <i>(Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)</i>		UCSD-07017
Application Number 09/788,11		Filed 02/15/2001
For A Universal Vaccine And Method For Treating Cancer Employing Telomerase Reverse Transcriptase		
Art Unit 1642		Examiner Ungar, S.
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.		
The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):		
	<u>Fee</u>	<u>Small Entity Fee</u>
<input type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$120	\$60
<input checked="" type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$450	\$225
<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$1020	\$510
<input type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$1590	\$795
<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$2160	\$1080
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		
<input checked="" type="checkbox"/> A check in the amount of the fee is enclosed.		
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		
<input type="checkbox"/> The Director has already been authorized to charge fees in this application to a Deposit Account.		
<input checked="" type="checkbox"/> The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 08-1290 I have enclosed a duplicate copy of this sheet.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
I am the	<input type="checkbox"/> applicant/inventor.	
	<input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).	
	<input checked="" type="checkbox"/> attorney or agent of record. Registration Number 51,934	
	<input type="checkbox"/> attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34	
		November 22, 2005
Signature		Date
Christine A. Lekutis		415.904.6500
Typed or printed name		Telephone Number

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

Total of forms are submitted.

This collection of information is required by 37 CFR 1.136(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.